Elite Pharmaceuticals, Inc. (ELTP)

Market Cap	520.73M
Revenue (ttm)	70.00M
Net Income (ttm)	-17.99M
Shares Out	1.07B
EPS (ttm)	-0.02
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	229,164
Average Volume	1,210,941
Open	0.494
Previous Close	0.500
Day's Range	0.473 - 0.500
52-Week Range	0.120 - 0.750
Beta	0.26
RSI	43.97
Earnings Date	Feb 13, 2025

About Elite Pharmaceuticals

Elite Pharmaceuticals, Inc., a specialty pharmaceutical company, engages in the development, manufacture, and sale of oral, controlled-release products, and generic pharmaceuticals. The company operates through Abbreviated New Drug Applications for Generic Pharmaceuticals and New Drug Applications for Branded Pharmaceuticals segments. It owns, licenses, manufactures, and sells various generic and oral dose pharmaceuticals products, such as Phentermine HCl 37.5mg tablets, and 15mg and 30mg capsules for the treatment of bariatrics under Adipex-P ...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 1997
• Employees: 64
• Stock Exchange: OTCMKTS
• Ticker Symbol: ELTP

Financial Performance

In 2023, Elite Pharmaceuticals's revenue was $56.63 million, an increase of 65.79% compared to the previous year's $34.16 million. Earnings were $20.11 million, an increase of 464.56%.